Compounds > mcn 5691
Page last updated: 2024-12-07

mcn 5691

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

McN 5691: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID127269
CHEMBL ID352255
SCHEMBL ID9218599
MeSH IDM0157107

Synonyms (26)

Synonym
rwj-26240
mcn-5691
mcn 5691
99254-95-2
CHEMBL352255
n-[2-(3,4-dimethoxyphenyl)ethyl]-4-[5-methoxy-2-(phenylethynyl)phenyl]-n-methylbutan-2-amine
n-[2-(3,4-dimethoxyphenyl)ethyl]-4-[5-methoxy-2-(2-phenylethynyl)phenyl]-n-methylbutan-2-amine
A813779
n-[2-(3,4-dimethoxyphenyl)ethyl]-4-[5-methoxy-2-(2-phenylethynyl)phenyl]-n-methyl-butan-2-amine
benzenepropanamine, n-(2-(3,4-dimethoxyphenyl)ethyl)-5-methoxy-n,alpha-dimethyl-2-(phenylethynyl)-
rwj 26240
n-(2-(3,4-dimethoxyphenyl)ethyl)-5-methoxy-n-dimethyl-2-(phenylethynyl)benzenepropanamine
n-(2-(3,4-dimethoxyphenyl)-ethyl)-5-methoxy-n,alphadimethyl-2-(phenylethynyl)benzenepropanamine
6nz1chr0u7 ,
rwj26240
unii-6nz1chr0u7
HQDXNTRZJRNPLD-UHFFFAOYSA-N
n-[2-(3,4-dimethoxyphenyl)ethyl]-5-methoxy-n,alpha-dimethyl-2-(phenylethynyl)benzenepropanamine
SCHEMBL9218599
CS-7359
mcn5691
HY-U00218
benzenepropanamine, n-(2-(3,4-dimethoxyphenyl)ethyl)-5-methoxy-n,.alpha.-dimethyl-2-(2-phenylethynyl)-
n-(2-(3,4-dimethoxyphenyl)ethyl)-5-methoxy-n,.alpha.-dimethyl-2-(2-phenylethynyl)benzenepropanamine
DTXSID40912815
AKOS040733699

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
") infusion of either McN-5691 at three dosage levels (0."( Effects of the novel calcium channel blocker, McN-5691, on cardiocirculatory dynamics and cardiac output distribution in conscious spontaneously hypertensive rat.
Brannan, MD; Carson, JR; Flaim, SF; Gill, A; Stranieri, MT, 1988)		0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID75198Concentration needed to elicit a 75% increase beyond control in coronary flow in ''Langendorff'', guinea pig heart (in vitro)1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
2-Ethynylbenzenealkanamines. A new class of calcium entry blockers.
AID165670In vitro inhibition of development of isometric tension, in response to KCl (60 uM) in rabbit aorta1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
2-Ethynylbenzenealkanamines. A new class of calcium entry blockers.
AID165790Inhibition of [Ca2+] influx in response to a stimulus of KCL (60 uM)1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
2-Ethynylbenzenealkanamines. A new class of calcium entry blockers.
AID75504Concentration needed to achieve a 75% increase in coronary blood flow in 'Langendorff', guinea pig heart (in vitro negative inotropic activity)1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
2-Ethynylbenzenealkanamines. A new class of calcium entry blockers.
AID165792Inhibition of [Ca2+] influx in response to a stimulus of norepinephrine (NE, 10 uM)1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
2-Ethynylbenzenealkanamines. A new class of calcium entry blockers.
AID185881Ability to lower blood pressure in the spontaneously hypertensive rat (SHR) at 30 mg/kg (p.o.)1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
2-Ethynylbenzenealkanamines. A new class of calcium entry blockers.
AID165788In vitro inhibition of development of isometric tension, in response to norepinephrine (NE, 10 uM) in rabbit aorta1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
2-Ethynylbenzenealkanamines. A new class of calcium entry blockers.
AID76313Concentration needed to achieve a 75% increase in coronary blood flow in 'Langendorff', guinea pig heart (in vitro Negative inotropic potency)1988Journal of medicinal chemistry, Mar, Volume: 31, Issue:3
2-Ethynylbenzenealkanamines. A new class of calcium entry blockers.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (28.57)18.7374
1990's4 (57.14)18.2507
2000's1 (14.29)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
verapamil
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.		2.3820aromatic ether;
nitrile;
polyether;
tertiary amino compound
nifedipine
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.		1.9710C-nitro compound;
dihydropyridine;
methyl ester		calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent
papaverine
Papaverine: An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels.. papaverine : A benzylisoquinoline alkaloid that is isoquinoline substituted by methoxy groups at positions 6 and 7 and a 3,4-dimethoxybenzyl group at position 1. It has been isolated from Papaver somniferum.		210benzylisoquinoline alkaloid;
dimethoxybenzene;
isoquinolines		antispasmodic drug;
vasodilator agent
laudanosine
laudanosine: opium alkaloid		210isoquinolines
diltiazem
Diltiazem: A benzothiazepine derivative with vasodilating action due to its antagonism of the actions of CALCIUM ion on membrane functions.. diltiazem : A 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate in which both stereocentres have S configuration. A calcium-channel blocker and vasodilator, it is used as the hydrochloride in the management of angina pectoris and hypertension.		2.39205-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetateantihypertensive agent;
calcium channel blocker;
vasodilator agent
diclofurime
diclofurime: RN given refers to parent cpd		210
ConditionIndicatedRelationship StrengthStudiesTrials
Blood Pressure, High
[description not available]		02.3720
Hypertension
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.		02.3720
Muscle Contraction
A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.		01.9710